Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
Jennifer L. Goralski, Jordana E. Hoppe, Marcus Mall, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 208, Iss. 1, pp. 59-67
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Cystic Fibrosis
Thida Ong, Bonnie W. Ramsey
JAMA (2023) Vol. 329, Iss. 21, pp. 1859-1859
Closed Access | Times Cited: 136
Cystic Fibrosis
Hartmut Grasemann, Félix Ratjen
New England Journal of Medicine (2023) Vol. 389, Iss. 18, pp. 1693-1707
Closed Access | Times Cited: 130
The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
Simon Y. Graeber, Marcus Mall
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1185-1198
Closed Access | Times Cited: 68
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
Jennifer L. Taylor‐Cousar, Paul D. Robinson, Michal Shteinberg, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1171-1184
Closed Access | Times Cited: 64
Standards for the care of people with cystic fibrosis; establishing and maintaining health
Kevin W Southern, C. Addy, Scott C. Bell, et al.
Journal of Cystic Fibrosis (2023) Vol. 23, Iss. 1, pp. 12-28
Open Access | Times Cited: 43
Cystic fibrosis
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 27
Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians
Vito Terlizzi, Philip M. Farrell
Current problems in pediatric and adolescent health care (2024) Vol. 54, Iss. 6, pp. 101637-101637
Closed Access | Times Cited: 24
Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis
Jennifer Loske, Mirjam Völler, Soeren Lukassen, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 209, Iss. 11, pp. 1338-1350
Open Access | Times Cited: 20
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman, et al.
The Lancet Respiratory Medicine (2025)
Open Access | Times Cited: 10
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Nicole Mayer-Hamblett, John P. Clancy, Raksha Jain, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 10, pp. 932-944
Open Access | Times Cited: 23
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles
Mirjam Stahl, Martha Dohna, Simon Y. Graeber, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 3, pp. 2400004-2400004
Open Access | Times Cited: 15
Update in paediatric asthma
Andrew Bush
Current Opinion in Pulmonary Medicine (2025)
Closed Access | Times Cited: 1
Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium
Simon Y. Graeber, Olaf Sommerburg, Yin Yu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study
Jochen G. Mainz, Karen Lester, Basil Elnazir, et al.
Journal of Cystic Fibrosis (2023)
Open Access | Times Cited: 19
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
Margarete Olivier, Alexandra Kavvalou, Matthias Welsner, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 18
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting
Valeria Daccò, Chiara Rosazza, Alessandra Mariani, et al.
Pediatric Pulmonology (2024)
Open Access | Times Cited: 7
Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis
Isabelle Sermet‐Gaudelus, Sihem Benaboud, S. Bui, et al.
The Lancet (2024) Vol. 404, Iss. 10448, pp. 117-120
Closed Access | Times Cited: 7
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
The Journal of Pediatrics (2024) Vol. 274, pp. 114176-114176
Closed Access | Times Cited: 7
Considerations for the use of inhaled antibiotics forPseudomonas aeruginosain people with cystic fibrosis receiving CFTR modulator therapy
Pierre–Régis Burgel, Manfred Ballmann, Pavel Dřevı́nek, et al.
BMJ Open Respiratory Research (2024) Vol. 11, Iss. 1, pp. e002049-e002049
Open Access | Times Cited: 6
Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis
Martina Cecchetti, Luca Scarallo, Paolo Lionetti, et al.
Paediatric Respiratory Reviews (2024)
Closed Access | Times Cited: 6
Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial
George M. Solomon, Rachel W. Linnemann, Rachel Rich, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 12, pp. 947-957
Closed Access | Times Cited: 5
Ocular development after highly effective modulator treatment early in life
Yimin Zhu, Danni Li, Felisa Reyes‐Ortega, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease
Hannah E Protich, Jean P. Molleston, Molly Bozic, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 6, pp. 1122-1128
Closed Access | Times Cited: 4
Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis
Kimberly G. Stephenson, Abby J. Lingle, K. Baumberger, et al.
Journal of Cystic Fibrosis (2023) Vol. 22, Iss. 6, pp. 996-1001
Closed Access | Times Cited: 10
Monitoring ETI effects over 1.7 years in an infant treated in utero, via breast milk and granules by repeated faecal elastase measurements
Dorothea Appelt, Teresa Fuchs, Johannes Eder, et al.
Journal of Cystic Fibrosis (2025)
Open Access
Page 1 - Next Page

Scroll to top